FDA Approves New Use for Reclast
The drug Reclast has just been approved by the FDA for a new purpose: the treatment and prevention of osteoporosis. Specifically, patients expected to be on glucocorticoids, or steroids, for at least 12 months can now use it.
During the trial, Reclast improved bone mineral density in patients who were on glucocorticoids for at least a year. Glucorticoids are widely used to treat inflammatory conditions, but can increase the risk of fractures if used on a long-term basis.
This is the fourth approved usage for the drug. It was first approved to treat postmenopausal osteoporosis is 2007 and has since been approved for patients at high risk for fractures or who suffer from Paget’s disease.
We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!